Pulmonary vein isolation for atrial fibrillation had similar recurrence rates across age groups (15.1%-18.4%, P>0.05), but stroke risk was higher in patients >60 years (3% vs 0%, P<0.05).
Observational (n=323)
Does age impact the outcomes and complications of pulmonary vein isolation in patients with drug-refractory symptomatic atrial fibrillation?
Pulmonary vein isolation is effective across all age groups for drug-refractory AF, but patients over 60 have a higher risk of procedural stroke.
p-value: p=>0.05
INTRODUCTION: A retrospective analysis was performed to define the impact of age on the outcomes and complications in patients undergoing pulmonary vein isolation (PVI). PVI is an evolving technique for the management of atrial fibrillation (AF). The impact of age on the risks, outcomes, and complications of PVI has not been well defined. METHODS AND RESULTS: A total of 323 patients (259 men and 64 women; age 18-79 years) underwent PVI for treatment of drug-refractory symptomatic AF. An ostial isolation of the pulmonary veins was done using a cooled-tip ablation catheter guided by circular mapping. The patients were divided into three groups based on age (group I: 60 years) and the results were compared. There were 106 patients in group I, 114 patients in group II, and 103 patients in group III (mean age 41.3 +/- 7.8 years, 55.4 +/- 2.75 years, and 66.6 +/- 4.18 years, respectively) who underwent PVI for paroxysmal (53.8%), persistent (10.8%), or permanent (35.3%) AF. Baseline characteristics were similar except for a higher prevalence of hypertension and/or structural heart disease in groups II and III (58% and 63% vs 33% in group I, respectively). The procedural variables were similar in all age groups. The overall risk of complications was similar in the three groups, except that the risk of stroke was significantly higher in patients >60 years of age (3% vs 0%; P 0.05). The risk of severe pulmonary vein stenosis (1.8%, 2.6%, and 0.9%, respectively) was low and did not vary with age. CONCLUSION: PVI is a safe and effective treatment for patients with drug-refractory symptomatic AF, and its benefits extend to all age groups. The risk of procedural complications, especially thromboembolic events, appears to be higher in the elderly age group. This observation needs to be considered while assessing potential candidates for the procedure.
Bhargava et al. (Thu,) conducted a observational in Drug-refractory symptomatic atrial fibrillation (n=323). Pulmonary vein isolation (PVI) vs. Age groups (<50, 51-60, >60 years) was evaluated on Recurrence rates of atrial fibrillation (p=>0.05). Pulmonary vein isolation for atrial fibrillation had similar recurrence rates across age groups (15.1%-18.4%, P>0.05), but stroke risk was higher in patients >60 years (3% vs 0%, P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: